• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Doug Kass
    • Bruce Kamich
    • Jim Cramer
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • Trifecta Stocks
  1. Home
  2. / Investing
  3. / Stocks

Pfizer Stock Slides Slightly as Drug-Maker Prepares Price Increases

Pfizer may have poked the bear.
By KEVIN CURRAN Nov 19, 2018 | 09:30 AM EST
Stocks quotes in this article: PFE

Pfizer Inc.'s (PFE) drug price increases that defy the oval office are provoking a mixed response.

Shares of the New York City-based pharmaceutical giant have remained largely flat to slightly negative in pre-market, adding further signs of uncertainty to what has been a tumultuous fourth quarter so far amid pressure from both President Trump and HHS Secretary Alex Azar on the pricing issue.

The company's announcement of price increases comes shortly after HHS Secretary Azar discussed problems with transparency and pricing controls in the industry. The company's statement appears to be cognizant of that criticism, positioning the price hike as a way to increase research and development of drugs while increasing rebates to insurance companies and pharmacy benefit managers.

"We believe the best means to address affordability of medicines is to reduce the growing out-of-pocket costs that consumers are facing due to high deductibles and co-insurance and ensure that patients receive the benefit of rebates at the pharmacy counter," CEO Ian Read said in in a statement.

Effective January 15, 2019, the list price of 10% of Pfizer's medicines, 41 products in total, will see price increases. For shareholders, this will bring in what Read has called a return to "business as normal."

"I expect that like most industries, we will look at our pricing situation in January and take decisions based on what the competitive set is and what our value proposition is in the new marketplace," he said on the company's third-quarter earnings call. "We've been working with the President on parts of the blueprint and I expect our approach by the end of year will be, what I would characterize as business as normal."

It is worth noting that Read will be succeeded by current COO Albert Bourla on January 1, 2019 -- shortly before the increase.

The price raises on 41 drugs marches the company towards its "normal" business swiftly before his start. In 2017, Pfizer charted double-digit increases across 91 drugs, according to the Financial Times.

Coming Into the Crosshairs

Such increases have brought the company under the microscope of the Trump administration already. Up to this point, the company has seemed content to kowtow to the White House blueprint of moderating prices.

The reversal of course might just draw an angry, and public, reproach from President Trump, given the public nature of his previous commendation.

Analysts are not optimistic on the prospects of a legislative debate around pricing.

"We think this enflames the debate around drug pricing, especially since it comes less than two weeks following an election that resulted in Democrat control of the House, with many having run on drug price controls/Medicare for All platforms," Wells Fargo analyst David Maris wrote in a research note on the hike. "Pfizer probably had no intent on testing lawmakers' resolve on addressing drug pricing, but it may just have done so."

As a result, he set an underweight rating for the entire large-cap pharmaceutical sector until more certainty on the political implications of pricing becomes apparent and the market determines how much of a price increase is acceptable.

For now, investors will need to watch the Twitter feeds of both the President and many drug-price conscious liberal leaders like Bernie Sanders, as a rare area of political agreement could bring regulatory action and more volatility to the shareholders of pharma stocks.

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

Employees of TheStreet are restricted from trading individual securities.

TAGS: Drug Approvals | Investing | Politics | Stocks | Pharmaceuticals | United States | Analyst Actions

More from Stocks

Bearish Bets: 2 Stocks You Should Consider Shorting This Week

Bob Lang
Apr 11, 2021 10:32 AM EDT

These names are displaying both quantitative and technical deterioration.

Kass: On the Market's Stairway to Heaven, Headwinds Abound

Doug Kass
Apr 10, 2021 12:00 PM EDT

You can rock on for now while the music is still playing, but be prepared for the inevitable 'out of the blue' sour note.

The 5 Pillars of Exceptional Trading

James "Rev Shark" DePorre
Apr 10, 2021 10:00 AM EDT

When you put them together, trading success is nearly inevitable.

Market's 'Superficial' Highs Are Only Skin Dip

James "Rev Shark" DePorre
Apr 9, 2021 4:36 PM EDT

You can't call this market overbought when so much of it isn't participating.

Pinterest: Double Top or Breakout Pending?

Bruce Kamich
Apr 9, 2021 3:00 PM EDT

What would I do in this case? Here's the logical choice.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 04:44 PM EDT PAUL PRICE

    Pretty Incredible + Hard to Believe

  • 11:18 AM EDT JAMES "REV SHARK" DEPORRE

    This Weekend on Real Money

    The 5 Pillars of Exceptional Trading
  • 08:05 AM EDT BOB LANG

    Bitcoin vs. Gold: Which Should You Invest In Now?

    Read my article TheStreet here!
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2021 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login